{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,7]],"date-time":"2026-05-07T19:25:12Z","timestamp":1778181912262,"version":"3.51.4"},"reference-count":33,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2015,10,14]],"date-time":"2015-10-14T00:00:00Z","timestamp":1444780800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Neurotox Res"],"published-print":{"date-parts":[[2016,1]]},"DOI":"10.1007\/s12640-015-9565-5","type":"journal-article","created":{"date-parts":[[2015,10,14]],"date-time":"2015-10-14T06:39:59Z","timestamp":1444804799000},"page":"105-117","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":92,"title":["Neutralizing Antibody and Botulinum Toxin Therapy: A Systematic Review and Meta-analysis"],"prefix":"10.1007","volume":"29","author":[{"given":"Margherita","family":"Fabbri","sequence":"first","affiliation":[]},{"given":"Giorgio","family":"Leodori","sequence":"additional","affiliation":[]},{"given":"Ricardo M.","family":"Fernandes","sequence":"additional","affiliation":[]},{"given":"Roongroj","family":"Bhidayasiri","sequence":"additional","affiliation":[]},{"given":"Maria Jose","family":"Marti","sequence":"additional","affiliation":[]},{"given":"Carlo","family":"Colosimo","sequence":"additional","affiliation":[]},{"given":"Joaquim J.","family":"Ferreira","sequence":"additional","affiliation":[]}],"member":"297","published-online":{"date-parts":[[2015,10,14]]},"reference":[{"issue":"1","key":"9565_CR1","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1111\/j.1468-1331.2010.03042.x","volume":"18","author":"A Albanese","year":"2011","unstructured":"Albanese A, Asmus F, Bhatia KP, Elia AE, Elibol B, Filippini G, Gasser T, Krauss JK, Nardocci N, Newton A, Valls-Sole J (2011) EFNS guidelines on diagnosis and treatment of primary dystonias. Eur J Neurol 18(1):5\u201318. doi: 10.1111\/j.1468-1331.2010.03042.x","journal-title":"Eur J Neurol"},{"key":"9565_CR2","doi-asserted-by":"crossref","first-page":"S68","DOI":"10.1002\/mds.20020","volume":"19","author":"MZ Atassi","year":"2004","unstructured":"Atassi MZ (2004) Basic immunological aspects of botulinum toxin therapy. Mov Disord 19:S68\u2013S84. doi: 10.1002\/mds.20020","journal-title":"Mov Disord"},{"issue":"7","key":"9565_CR3","doi-asserted-by":"crossref","first-page":"782","DOI":"10.1016\/j.imbio.2010.12.009","volume":"216","author":"MZ Atassi","year":"2011","unstructured":"Atassi MZ, Dolimbek BZ, Jankovic J, Steward LE, Aoki KR (2011) Regions of botulinum neurotoxin A light chain recognized by human anti-toxin antibodies from cervical dystonia patients immunoresistant to toxin treatment. The antigenic structure of the active toxin recognized by human antibodies. Immunobiology 216(7):782\u2013792. doi: 10.1016\/j.imbio.2010.12.009","journal-title":"Immunobiology"},{"issue":"2","key":"9565_CR4","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.2165\/11599840-000000000-00000","volume":"26","author":"R Benecke","year":"2012","unstructured":"Benecke R (2012) Clinical relevance of botulinum toxin immunogenicity. BioDrugs 26(2):e1\u2013e9. doi: 10.2165\/11599840-000000000-00000","journal-title":"BioDrugs"},{"issue":"1","key":"9565_CR5","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1212\/WNL.46.1.26","volume":"46","author":"G Borodic","year":"1996","unstructured":"Borodic G, Johnson E, Goodnough M, Schantz E (1996) Botulinum toxin therapy, immunologic resistance, and problems with available materials. Neurology 46(1):26\u201329","journal-title":"Neurology"},{"key":"9565_CR6","first-page":"348","volume-title":"Parkinson\u2019s disease and movement disorders","author":"MF Brin","year":"2007","unstructured":"Brin MF (2007) Treatment of dystonia. In: Jankovic J, Tolosa E (eds) Parkinson\u2019s disease and movement disorders. Lippincott Williams & Wilkins, Philadelphia, pp 348\u2013355"},{"issue":"10","key":"9565_CR7","doi-asserted-by":"crossref","first-page":"1353","DOI":"10.1002\/mds.22157","volume":"23","author":"MF Brin","year":"2008","unstructured":"Brin MF, Comella CL, Jankovic J, Lai F, Naumann M, Group CDBS (2008) Long-term treatment with botulinum toxin type A in cervical dystonia has low immunogenicity by mouse protection assay. Mov Disord 23(10):1353\u20131360. doi: 10.1002\/mds.22157","journal-title":"Mov Disord"},{"issue":"5","key":"9565_CR8","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1097\/WNF.0b013e318263163c","volume":"35","author":"RB Chinnapongse","year":"2012","unstructured":"Chinnapongse RB, Lew MF, Ferreira JJ, Gullo KL, Nemeth PR, Zhang Y (2012) Immunogenicity and long-term efficacy of botulinum toxin type B in the treatment of cervical dystonia: report of 4 prospective, multicenter trials. Clin Neuropharmacol 35(5):215\u2013223. doi: 10.1097\/WNF.0b013e318263163c","journal-title":"Clin Neuropharmacol"},{"issue":"4","key":"9565_CR9","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1007\/s12640-012-9314-y","volume":"22","author":"C Colosimo","year":"2012","unstructured":"Colosimo C, Tiple D, Berardelli A (2012) Efficacy and safety of long-term botulinum toxin treatment in craniocervical dystonia: a systematic review. Neurotox Res 22(4):265\u2013273. doi: 10.1007\/s12640-012-9314-y","journal-title":"Neurotox Res"},{"issue":"10","key":"9565_CR10","doi-asserted-by":"crossref","first-page":"1737","DOI":"10.1002\/mds.21051","volume":"21","author":"C Cordivari","year":"2006","unstructured":"Cordivari C, Misra VP, Vincent A, Catania S, Bhatia KP, Lees AJ (2006) Secondary nonresponsiveness to botulinum toxin A in cervical dystonia: the role of electromyogram-guided injections, botulinum toxin A antibody assay, and the extensor digitorum brevis test. Mov Disord 21(10):1737\u20131741. doi: 10.1002\/mds.21051","journal-title":"Mov Disord"},{"issue":"4","key":"9565_CR11","doi-asserted-by":"crossref","first-page":"742","DOI":"10.1016\/j.eururo.2011.07.002","volume":"60","author":"F Cruz","year":"2011","unstructured":"Cruz F, Herschorn S, Aliotta P, Brin M, Thompson C, Lam W, Daniell G, Heesakkers J, Haag-Molkenteller C (2011) Efficacy and safety of onabotulinumtoxinA in patients with urinary incontinence due to neurogenic detrusor overactivity: a randomised, double-blind, placebo-controlled trial. Eur Urol 60(4):742\u2013750. doi: 10.1016\/j.eururo.2011.07.002","journal-title":"Eur Urol"},{"issue":"5","key":"9565_CR12","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1016\/j.molimm.2006.03.011","volume":"44","author":"BZ Dolimbek","year":"2007","unstructured":"Dolimbek BZ, Aoki KR, Steward LE, Jankovic J, Atassi MZ (2007) Mapping of the regions on the heavy chain of botulinum neurotoxin A (BoNT\/A) recognized by antibodies of cervical dystonia patients with immunoresistance to BoNT\/A. Mol Immunol 44(5):1029\u20131041. doi: 10.1016\/j.molimm.2006.03.011","journal-title":"Mol Immunol"},{"key":"9565_CR13","doi-asserted-by":"crossref","first-page":"S92","DOI":"10.1002\/mds.20022","volume":"19","author":"D Dressler","year":"2004","unstructured":"Dressler D (2004) Clinical presentation and management of antibody-induced failure of botulinum toxin therapy. Mov Disord 19:S92\u2013S100","journal-title":"Mov Disord"},{"key":"9565_CR14","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1111\/j.1468-1331.2006.01439.x","volume":"13","author":"D Dressler","year":"2006","unstructured":"Dressler D, Hallett M (2006) Immunological aspects of Botox, Dysport and Myobloc\/NeuroBloc. Eur J Neurol 13:11\u201315. doi: 10.1111\/j.1468-1331.2006.01439.x","journal-title":"Eur J Neurol"},{"issue":"1","key":"9565_CR15","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1006\/exnr.1997.6580","volume":"147","author":"H Goschel","year":"1997","unstructured":"Goschel H, Wohlfarth K, Frevert J, Dengler R, Bigalke H (1997) Botulinum A toxin therapy: neutralizing and nonneutralizing antibodies\u2013therapeutic consequences. Exp Neurol 147(1):96\u2013102. doi: 10.1006\/exnr.1997.6580","journal-title":"Exp Neurol"},{"issue":"2","key":"9565_CR16","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1002\/mds.870090216","volume":"9","author":"P Greene","year":"1994","unstructured":"Greene P, Fahn S, Diamond B (1994) Development of resistance to botulinum toxin type A in patients with torticollis. Mov Disord 9(2):213\u2013217. doi: 10.1002\/mds.870090216","journal-title":"Mov Disord"},{"issue":"6832","key":"9565_CR17","doi-asserted-by":"crossref","first-page":"959","DOI":"10.1136\/bmj.304.6832.959-a","volume":"304","author":"P Hambleton","year":"1992","unstructured":"Hambleton P, Cohen HE, Palmer BJ, Melling J (1992) Antitoxins and botulinum toxin treatment. BMJ 304(6832):959\u2013960","journal-title":"BMJ"},{"issue":"6","key":"9565_CR18","doi-asserted-by":"crossref","first-page":"1624","DOI":"10.1212\/WNL.50.6.1624","volume":"50","author":"PA Hanna","year":"1998","unstructured":"Hanna PA, Jankovic J (1998) Mouse bioassay versus Western blot assay for botulinum toxin antibodies: correlation with clinical response. Neurology 50(6):1624\u20131629","journal-title":"Neurology"},{"key":"9565_CR19","first-page":"93","volume-title":"Therapy with botulinum toxin","author":"CL Hatheway","year":"1994","unstructured":"Hatheway CL, Dang C (1994) Immunogenicity of the neurotoxins of Clostridium botulinum. In: Jankovic J, Hallett M (eds) Therapy with botulinum toxin. Marcel Dekker, New York, pp 93\u2013108"},{"issue":"12","key":"9565_CR20","doi-asserted-by":"crossref","first-page":"1253","DOI":"10.1001\/archneur.1991.00530240057020","volume":"48","author":"J Jankovic","year":"1991","unstructured":"Jankovic J, Schwartz KS (1991) Clinical correlates of response to botulinum toxin injections. Arch Neurol 48(12):1253\u20131256","journal-title":"Arch Neurol"},{"issue":"9","key":"9565_CR21","doi-asserted-by":"crossref","first-page":"1743","DOI":"10.1212\/WNL.45.9.1743","volume":"45","author":"J Jankovic","year":"1995","unstructured":"Jankovic J, Schwartz K (1995) Response and immunoresistance to botulinum toxin injections. Neurology 45(9):1743\u20131746","journal-title":"Neurology"},{"issue":"7","key":"9565_CR22","doi-asserted-by":"crossref","first-page":"1186","DOI":"10.1212\/01.WNL.0000055087.96356.BB","volume":"60","author":"J Jankovic","year":"2003","unstructured":"Jankovic J, Vuong KD, Ahsan J (2003) Comparison of efficacy and immunogenicity of original versus current botulinum toxin in cervical dystonia. Neurology 60(7):1186\u20131188","journal-title":"Neurology"},{"issue":"12","key":"9565_CR23","doi-asserted-by":"crossref","first-page":"2233","DOI":"10.1212\/01.wnl.0000249308.66959.43","volume":"67","author":"J Jankovic","year":"2006","unstructured":"Jankovic J, Hunter C, Dolimbek BZ, Dolimbek GS, Adler CH, Brashear A, Comella CL, Gordon M, Riley DE, Sethi K, Singer C, Stacy M, Tarsy D, Atassi MZ (2006) Clinico-immunologic aspects of botulinum toxin type B treatment of cervical dystonia. Neurology 67(12):2233\u20132235. doi: 10.1212\/01.wnl.0000249308.66959.43","journal-title":"Neurology"},{"issue":"4","key":"9565_CR24","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1007\/s004150050345","volume":"246","author":"KR Kessler","year":"1999","unstructured":"Kessler KR, Skutta M, Benecke R (1999) Long-term treatment of cervical dystonia with botulinum toxin A: efficacy, safety, and antibody frequency. German Dystonia Study Group. J Neurol 246(4):265\u2013274","journal-title":"J Neurol"},{"issue":"5","key":"9565_CR25","doi-asserted-by":"crossref","first-page":"1062","DOI":"10.1542\/peds.108.5.1062","volume":"108","author":"LA Koman","year":"2001","unstructured":"Koman LA, Brashear A, Rosenfeld S, Chambers H, Russman B, Rang M, Root L, Ferrari E, de Yebenes Garcia, Prous J, Smith BP, Turkel C, Walcott JM, Molloy PT (2001) Botulinum toxin type a neuromuscular blockade in the treatment of equinus foot deformity in cerebral palsy: a multicenter, open-label clinical trial. Pediatrics 108(5):1062\u20131071","journal-title":"Pediatrics"},{"issue":"4","key":"9565_CR26","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1097\/WNF.0b013e3181914d0a","volume":"32","author":"O Lange","year":"2009","unstructured":"Lange O, Bigalke H, Dengler R, Wegner F, deGroot M, Wohlfarth K (2009) Neutralizing antibodies and secondary therapy failure after treatment with botulinum toxin type A: much ado about nothing? Clin Neuropharmacol 32(4):213\u2013218. doi: 10.1097\/WNF.0b013e3181914d0a","journal-title":"Clin Neuropharmacol"},{"issue":"5","key":"9565_CR27","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1002\/mds.20376","volume":"20","author":"NI Mejia","year":"2005","unstructured":"Mejia NI, Vuong KD, Jankovic J (2005) Long-term botulinum toxin efficacy, safety, and immunogenicity. Mov Disord 20(5):592\u2013597. doi: 10.1002\/mds.20376","journal-title":"Mov Disord"},{"issue":"12","key":"9565_CR28","doi-asserted-by":"crossref","first-page":"1535","DOI":"10.1136\/jnnp.57.12.1535","volume":"57","author":"T Mezaki","year":"1994","unstructured":"Mezaki T, Kaji R, Hamano T, Nagamine T, Shibasaki H, Shimizu T, Kimura J (1994) Optimisation of botulinum treatment for cervical and axial dystonias: experience with a Japanese type A toxin. J Neurol Neurosurg Psychiatrym 57(12):1535\u20131537","journal-title":"J Neurol Neurosurg Psychiatrym"},{"issue":"5","key":"9565_CR29","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1179\/174313209X405137","volume":"31","author":"B Mohammadi","year":"2009","unstructured":"Mohammadi B, Buhr N, Bigalke H, Krampfl K, Dengler R, Kollewe K (2009) A long-term follow-up of botulinum toxin A in cervical dystonia. Neurol Res 31(5):463\u2013466. doi: 10.1179\/174313209X405137","journal-title":"Neurol Res"},{"issue":"2","key":"9565_CR30","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1007\/s00702-012-0893-9","volume":"120","author":"M Naumann","year":"2013","unstructured":"Naumann M, Boo LM, Ackerman AH, Gallagher CJ (2013) Immunogenicity of botulinum toxins. J Neural Transm 120(2):275\u2013290. doi: 10.1007\/s00702-012-0893-9","journal-title":"J Neural Transm"},{"issue":"2","key":"9565_CR31","doi-asserted-by":"crossref","first-page":"249","DOI":"10.3390\/toxins5020249","volume":"5","author":"J Ramirez-Castaneda","year":"2013","unstructured":"Ramirez-Castaneda J, Jankovic J (2013) Long-term efficacy and safety of botulinum toxin injections in dystonia. Toxins (Basel) 5(2):249\u2013266. doi: 10.3390\/toxins5020249","journal-title":"Toxins (Basel)"},{"issue":"5","key":"9565_CR32","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1111\/j.1442-2042.2008.02016.x","volume":"15","author":"H Schulte-Baukloh","year":"2008","unstructured":"Schulte-Baukloh H, Bigalke H, Miller K, Heine G, Pape D, Lehmann J, Knispel HH (2008) Botulinum neurotoxin type A in urology: antibodies as a cause of therapy failure. Int J Urol 15(5):407\u2013415. doi: 10.1111\/j.1442-2042.2008.02016.x","journal-title":"Int J Urol"},{"issue":"9","key":"9565_CR33","doi-asserted-by":"crossref","first-page":"1715","DOI":"10.1212\/WNL.43.9.1715","volume":"43","author":"M Zuber","year":"1993","unstructured":"Zuber M, Sebald M, Bathien N, de Recondo J, Rondot P (1993) Botulinum antibodies in dystonic patients treated with type A botulinum toxin: frequency and significance. Neurology 43(9):1715\u20131718","journal-title":"Neurology"}],"container-title":["Neurotoxicity Research"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12640-015-9565-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s12640-015-9565-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12640-015-9565-5","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,6,2]],"date-time":"2019-06-02T09:31:30Z","timestamp":1559467890000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s12640-015-9565-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,10,14]]},"references-count":33,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2016,1]]}},"alternative-id":["9565"],"URL":"https:\/\/doi.org\/10.1007\/s12640-015-9565-5","relation":{},"ISSN":["1029-8428","1476-3524"],"issn-type":[{"value":"1029-8428","type":"print"},{"value":"1476-3524","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,10,14]]}}}